Long-term safety follow-up for people who received cell or gene therapy
Monitors long-term safety of people previously given AstraZeneca cell or gene therapies.
Plain-language title generated from the registry record
Registry title: LTFU for All Cell and Gene Therapy Studies
Key facts
- Where
- East Melbourne, AustraliaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received a cell or gene therapy in another AstraZeneca study. It checks their long-term safety for up to 15 years after their last treatment.
- Age
- 18 Years to 130 Years
- Sex
- All sexes can join.
- Earlier treatment
- Must have received a cell or gene therapy in another AstraZeneca study.
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06194461, who can take part
Where in Australia
- East MelbourneHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06194461
- Record updated
- 27 June 2025
- Original description
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.Read full original descriptionShow less
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Inclusion: The participant has received a cell or gene therapy in another AstraZeneca protocol; Provision of signed and dated, written informed consent before any study-specific procedures.
Exclusion: Not applicable; -.